Business Context and Reporting Period
Company: Arrowhead Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 12, 2026
Event: Entry into a Material Definitive Agreement involving the issuance of convertible senior notes and related capped call transactions.
Key Financial Metrics and Transaction Details
- Debt Issuance: $700,000,000 aggregate principal amount of 0.00% Convertible Senior Notes due 2032.
- Over-Allotment: The full $75,000,000 over-allotment option was exercised by underwriters, included in the total $700 million issuance.
- Interest Rate: 0.00% (no regular interest or accretion). Special interest may accrue up to 0.50% annually upon failure to file certain SEC reports.
- Maturity Date: January 15, 2032.
- Conversion Price: Approximately $87.07 per share (Initial conversion rate: 11.4844 shares per $1,000 principal).
- Capped Call Cost: Approximately $47.9 million.
- Capped Call Cap Price: Approximately $119.33 per share (approx. 85.0% premium over the public offering price).
Material Changes and Transaction Structure
The Company has significantly altered its capital structure by issuing zero-coupon convertible debt. Key structural features include:
- Seniority: Notes are senior unsecured obligations, equal to existing senior unsecured debt but structurally subordinated to subsidiary liabilities.
- Conversion Rights:
- Before October 15, 2031: Convertible only upon specific events.
- After October 15, 2031: Convertible at any time until the second trading day before maturity.
- Settlement: Cash, shares, or a combination at the Company's election.
- Redemption: Company may redeem notes on or after January 16, 2029, if the stock price exceeds 130% of the conversion price for at least 20 of the preceding 30 trading days.
- Make-Whole Provisions: Conversion rates may increase upon "Make-Whole Fundamental Changes" or if notes are called for redemption.
Outlook, Risks, and Contingencies
- Dilution Management: The Company entered into capped call transactions to offset potential dilution and cash payments upon conversion, subject to the $119.33 cap price.
- Events of Default: Includes payment defaults, failure to convert, bankruptcy, and defaults on other indebtedness of at least $60,000,000. Bankruptcy events trigger immediate acceleration of all notes.
- Reporting Covenants: Failure to comply with reporting covenants may result in special interest accruals rather than immediate default, at the Company's option.
- Fundamental Change Repurchase: Noteholders may require repurchase at par plus accrued interest if a "Fundamental Change" (e.g., business combination, delisting) occurs.
Investor Verification Checklist
- Verify the exact cash proceeds received after deducting underwriting discounts and the $47.9 million cost of capped call transactions.
- Confirm the current trading price of ARWR common stock relative to the $87.07 conversion price and $119.33 cap price to assess immediate dilution risk.
- Review the full text of the Indenture (Exhibits 4.1 and 4.2) for specific definitions of "Fundamental Change" and "Make-Whole Fundamental Change."
- Assess the Company's liquidity position post-issuance to ensure ability to meet potential cash settlement obligations upon conversion.
- Monitor compliance with SEC reporting requirements to avoid triggering the 0.50% special interest penalty.